Luke Peterson, MD
Ophthalmology · Matthews, NCNPI 1659698967
Payments from drug & device makers
Across 320 payments — averaging $41.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$5K
- Alcon$3K
- AbbVie$2K
- Novartis$612
- Sun Pharmaceutical Industries Inc.$505
- Rxsight Inc$423
- plus $2K from 15 others
What the payments were for
- Consulting fees$1,50011%
- Speaking & faculty fees$2,50019%
- Food & beverage$9,14369%
- Gifts$1801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 26 | $5,110 |
| Alcon | 58 | $2,718 |
| AbbVie(2 entities) | 106 | $1,898 |
| Novartis | 25 | $612 |
| Sun Pharmaceutical Industries Inc. | 32 | $505 |
| Rxsight Inc | 2 | $423 |
| Sight Sciences, Inc. | 10 | $251 |
| Bausch & Lomb Americas Inc. | 7 | $233 |
| Ivantis, Inc | 3 | $207 |
| Kala Pharmaceuticals, Inc. | 6 | $185 |
| Aerie Pharmaceuticals, Inc. | 11 | $184 |
| Glaukos Corporation | 2 | $179 |
| Harrow Eye, LLC | 7 | $169 |
| Biotissue Holdings Inc. | 3 | $126 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $126 |
| Tarsus Pharmaceuticals, Inc. | 3 | $109 |
| Rayner Intraocular Lenses Limited | 4 | $84 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $70 |
| Oyster Point Pharma, Inc. | 4 | $67 |
| Dompe US, Inc. | 2 | $50 |
| Omeros Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$4,647
- Kahook Dual Blade$4,647
- Hydrus Microstent$811
- Clareon$393
- RXSIGHT CONTACT LENS$315
- RXSIGHT INJECTOR HANDPIECE$315
- RXSIGHT INJECTOR CARTRIDGE$315
- LIGHT ADJUSTABLE LENS (LAL)$315
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$315
- Clearpath$296
- Streamline$296
- DURYSTA$250
- iStent Infinite$149
- iDoseTR$149
- PanOptix$144
- LenSx$144
- Unity$141
- Via360$139
- ILUX$117
- LUMIGAN$113
How this compares
$13,323 in reported general payments places this provider in the 85th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 220 | $111,172 |
| RestasisCyclosporine | 86 | $107,862 |
| XiidraLifitegrast | 62 | $91,929 |
| LumiganBimatoprost | 152 | $84,078 |
| RocklatanNetarsudil Mesylat/Latanoprost | 59 | $32,745 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 115 | $27,613 |
| CombiganBrimonidine Tartrate/Timolol | 64 | $26,212 |
| Prednisolone Acetate | 650 | $25,849 |
| Latanoprost | 1,866 | $22,374 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 110 | $18,975 |
| Travoprost | 101 | $18,021 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,030 | $17,344 |
| Cyclosporine | 33 | $14,668 |
| Brimonidine Tartrate | 538 | $11,850 |
| RhopressaNetarsudil Mesylate | 26 | $11,832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,898 | $229,896334 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $233 | $203,102282 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $184 | $44,57785 claims |
| AlconSimbrinza | $2,718 | $27,613115 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $505 | $10,65615 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $126 | $3,46136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Matthews
- Glenn JaffeDurham$38.5M
- Lejla VajzovicDurham$7.5M
- Andrew AntoszykCharlotte$4M
- Majda HadziahmetovicDurham$2.4M
- Preeya GuptaRaleigh$2M
- Thomas WilliamsHickory$1.8M
- James HarrisHickory$1.4M
- Rajiv ShahWinston Salem$1.3M
- Patrick KeltyHickory$1.1M
- Julie WoodwardDurham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.